Genetics of the polycross

D. Schoen,W. Cheliak

DOI: https://doi.org/10.1007/BF00288851

IF: 5.4

1987-09-01

Theoretical and Applied Genetics

Abstract:

What problem does this paper attempt to address?

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis

Atsuyuki Watanabe,Masao Iwagami,Jun Yasuhara,Hisato Takagi,Toshiki Kuno

DOI: https://doi.org/10.1016/j.vaccine.2023.02.008

IF: 4.169

2023-02-11

Vaccine

Abstract:Background The relationship between coronavirus disease 2019 (COVID-19) vaccination and long COVID has not been firmly established. We conducted a systematic review and meta -analysis to evaluate the association between COVID-19 vaccination and long COVID. Methods PubMed and EMBASE databases were searched on September 2022 without language restrictions ( CRD42022360399) to identify prospective trials and observational studies comparing patients with and without vaccination before severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We also included studies reporting symptomatic changes of ongoing long COVID following vaccination among those with a history of SARS-CoV-2 infection. Odds ratios (ORs) for each outcome were synthesized using a random-effects model. Symptomatic changes after vaccination were synthesized by a one-group meta -analysis. Results Six observational studies involving 536,291 unvaccinated and 84,603 vaccinated (before SARS-CoV-2 infection) patients (mean age, 41.2–66.6; female, 9.0–67.3%) and six observational studies involving 8,199 long COVID patients (mean age, 40.0 to 53.5; female, 22.2–85.9%) who received vaccination after SARS-CoV-2 infection were included. Two-dose vaccination was associated with a lower risk of long COVID compared to no vaccination (OR, 0.64; 95% confidence interval [CI], 0.45–0.92) and one-dose vaccination (OR, 0.60; 95% CI, 0.43–0.83). Two-dose vaccination compared to no vaccination was associated with a lower risk of persistent fatigue (OR, 0.62; 95% CI, 0.41–0.93) and pulmonary disorder (OR, 0.50; 95% CI, 0.47–0.52). Among those with ongoing long COVID symptoms, 54.4% (95% CI, 34.3–73.1%) did not report symptomatic changes following vaccination, while 20.3% (95% CI, 8.1–42.4%) experienced symptomatic improvement after two weeks to six months of COVID-19 vaccination. Conclusions COVID-19 vaccination before SARS-CoV-2 infection was associated with a lower risk of long COVID, while most of those with ongoing long COVID did not experience symptomatic changes following vaccination.

immunology,medicine, research & experimental
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Hannah E. Davis,Gina S. Assaf,Lisa McCorkell,Hannah Wei,Ryan J. Low,Yochai Re'em,Signe Redfield,Jared P. Austin,Athena Akrami

DOI: https://doi.org/10.1016/j.eclinm.2021.101019

IF: 15.1

2021-08-01

EClinicalMedicine

Abstract:BackgroundA significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.MethodsWe conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health.FindingsFor the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19.InterpretationPatients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.FundingAll authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).
Attributes and predictors of long COVID

Carole H. Sudre,Benjamin Murray,Thomas Varsavsky,Mark S. Graham,Rose S. Penfold,Ruth C. Bowyer,Joan Capdevila Pujol,Kerstin Klaser,Michela Antonelli,Liane S. Canas,Erika Molteni,Marc Modat,M. Jorge Cardoso,Anna May,Sajaysurya Ganesh,Richard Davies,Long H. Nguyen,David A. Drew,Christina M. Astley,Amit D. Joshi,Jordi Merino,Neli Tsereteli,Tove Fall,Maria F. Gomez,Emma L. Duncan,Cristina Menni,Frances M. K. Williams,Paul W. Franks,Andrew T. Chan,Jonathan Wolf,Sebastien Ourselin,Tim Spector,Claire J. Steves

DOI: https://doi.org/10.1038/s41591-021-01292-y

IF: 82.9

2021-03-10

Nature Medicine

Abstract:Reports of long-lasting coronavirus disease 2019 (COVID-19) symptoms, the so-called 'long COVID', are rising but little is known about prevalence, risk factors or whether it is possible to predict a protracted course early in the disease. We analyzed data from 4,182 incident cases of COVID-19 in which individuals self-reported their symptoms prospectively in the COVID Symptom Study app<sup><a href="/articles/s41591-021-01292-y#ref-CR1">1</a></sup>. A total of 558 (13.3%) participants reported symptoms lasting ≥28 days, 189 (4.5%) for ≥8 weeks and 95 (2.3%) for ≥12 weeks. Long COVID was characterized by symptoms of fatigue, headache, dyspnea and anosmia and was more likely with increasing age and body mass index and female sex. Experiencing more than five symptoms during the first week of illness was associated with long COVID (odds ratio = 3.53 (2.76–4.50)). A simple model to distinguish between short COVID and long COVID at 7 days (total sample size, <i>n</i> = 2,149) showed an area under the curve of the receiver operating characteristic curve of 76%, with replication in an independent sample of 2,472 individuals who were positive for severe acute respiratory syndrome coronavirus 2. This model could be used to identify individuals at risk of long COVID for trials of prevention or treatment and to plan education and rehabilitation services.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Effect of covid-19 vaccination on long covid: systematic review

Oyungerel Byambasuren,Paulina Stehlik,Justin Clark,Kylie Alcorn,Paul Glasziou

DOI: https://doi.org/10.1136/bmjmed-2022-000385

2023-02-01

BMJ Medicine

Abstract:Objective To determine the effect of covid-19 vaccination, given before and after acute infection with the SARS-CoV-2 virus, or after a diagnosis of long covid, on the rates and symptoms of long covid. Design Systematic review. Data sources PubMed, Embase, and Cochrane covid-19 trials, and Europe PubMed Central (Europe PMC) for preprints, from 1 January 2020 to 3 August 2022. Eligibility criteria for selecting studies Trials, cohort studies, and case-control studies reporting on patients with long covid and symptoms of long covid, with vaccination before and after infection with the SARS-CoV-2 virus, or after a diagnosis of long covid. Risk of bias was assessed with the ROBINS-I tool. Results 1645 articles were screened but no randomised controlled trials were found. 16 observational studies from five countries (USA, UK, France, Italy, and the Netherlands) were identified that reported on 614 392 patients. The most common symptoms of long covid that were studied were fatigue, cough, loss of sense of smell, shortness of breath, loss of taste, headache, muscle ache, difficulty sleeping, difficulty concentrating, worry or anxiety, and memory loss or confusion. 12 studies reported data on vaccination before infection with the SARS-CoV-2 virus, and 10 showed a significant reduction in the incidence of long covid: the odds ratio of developing long covid with one dose of vaccine ranged from 0.22 to 1.03; with two doses, odds ratios were 0.25-1; with three doses, 0.16; and with any dose, 0.48-1.01. Five studies reported on vaccination after infection, with odds ratios of 0.38-0.91. The high heterogeneity between studies precluded any meaningful meta-analysis. The studies failed to adjust for potential confounders, such as other protective behaviours and missing data, thus increasing the risk of bias and decreasing the certainty of evidence to low. Conclusions Current studies suggest that covid-19 vaccines might have protective and therapeutic effects on long covid. More robust comparative observational studies and trials are needed, however, to clearly determine the effectiveness of vaccines in preventing and treating long covid. Protocol registration Open Science Framework https://osf.io/e8jdy .
Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults

Hannah E Maier,Theresa Kowalski-Dobson,Ashley Eckard,Carmen Gherasim,David Manthei,Alyssa Meyers,Dawson Davis,Kevin Bakker,Kathleen Lindsey,Zijin Chu,Lauren Warsinske,Matthew Arnold,Anna Buswinka,Emily Stoneman,Riccardo Valdez,Aubree Gordon

DOI: https://doi.org/10.1093/ofid/ofae039

2024-01-23

Open Forum Infectious Diseases

Abstract:Abstract Background The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. Methods The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Results Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22–.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: −2.70 [95% CI, −1.68 to −3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0.07). Conclusions Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.

immunology,infectious diseases,microbiology
SARS-CoV-2-specific CD8+ T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years

Louise C Rowntree,Jennifer Audsley,Lilith F Allen,Hayley A McQuilten,Ruth R Hagen,Priyanka Chaurasia,Jan Petersen,Dene R Littler,Hyon-Xhi Tan,Lydia Murdiyarso,Jennifer R Habel,Isabelle J H Foo,Wuji Zhang,Elizabeth R V Ten Berge,Hanujah Ganesh,Prathanporn Kaewpreedee,Kelly W K Lee,Samuel M S Cheng,Janette S Y Kwok,Dhilshan Jayasinghe,Stephanie Gras,Jennifer A Juno,Adam K Wheatley,Stephen J Kent,Jamie Rossjohn,Allen C Cheng,Tom C Kotsimbos,Jason A Trubiano,Natasha E Holmes,Ken Ka Pang Chan,David S C Hui,Malik Peiris,Leo L M Poon,Sharon R Lewin,Peter C Doherty,Irani Thevarajan,Sophie A Valkenburg,Katherine Kedzierska,Thi H O Nguyen

DOI: https://doi.org/10.1073/pnas.2411428121

2024-09-24

Abstract:Long COVID occurs in a small but important minority of patients following COVID-19, reducing quality of life and contributing to healthcare burden. Although research into underlying mechanisms is evolving, immunity is understudied. SARS-CoV-2-specific T cell responses are of key importance for viral clearance and COVID-19 recovery. However, in long COVID, the establishment and persistence of SARS-CoV-2-specific T cells are far from clear, especially beyond 12 mo postinfection and postvaccination. We defined ex vivo antigen-specific B cell and T cell responses and their T cell receptors (TCR) repertoires across 2 y postinfection in people with long COVID. Using 13 SARS-CoV-2 peptide-HLA tetramers, spanning 11 HLA allotypes, as well as spike and nucleocapsid probes, we tracked SARS-CoV-2-specific CD8+ and CD4+ T cells and B-cells in individuals from their first SARS-CoV-2 infection through primary vaccination over 24 mo. The frequencies of ORF1a- and nucleocapsid-specific T cells and B cells remained stable over 24 mo. Spike-specific CD8+ and CD4+ T cells and B cells were boosted by SARS-CoV-2 vaccination, indicating immunization, in fully recovered and people with long COVID, altered the immunodominance hierarchy of SARS-CoV-2 T cell epitopes. Meanwhile, influenza-specific CD8+ T cells were stable across 24 mo, suggesting no bystander-activation. Compared to total T cell populations, SARS-CoV-2-specific T cells were enriched for central memory phenotype, although the proportion of central memory T cells decreased following acute illness. Importantly, TCR repertoire composition was maintained throughout long COVID, including postvaccination, to 2 y postinfection. Overall, we defined ex vivo SARS-CoV-2-specific B cells and T cells to understand primary and recall responses, providing key insights into antigen-specific responses in people with long COVID.
Symptoms and risk factors for long COVID in non-hospitalized adults

Anuradhaa Subramanian,Krishnarajah Nirantharakumar,Sarah Hughes,Puja Myles,Tim Williams,Krishna M. Gokhale,Tom Taverner,Joht Singh Chandan,Kirsty Brown,Nikita Simms-Williams,Anoop D. Shah,Megha Singh,Farah Kidy,Kelvin Okoth,Richard Hotham,Nasir Bashir,Neil Cockburn,Siang Ing Lee,Grace M. Turner,Georgios V. Gkoutos,Olalekan Lee Aiyegbusi,Christel McMullan,Alastair K. Denniston,Elizabeth Sapey,Janet M. Lord,David C. Wraith,Edward Leggett,Clare Iles,Tom Marshall,Malcolm J. Price,Steven Marwaha,Elin Haf Davies,Louise J. Jackson,Karen L. Matthews,Jenny Camaradou,Melanie Calvert,Shamil Haroon

DOI: https://doi.org/10.1038/s41591-022-01909-w

IF: 82.9

2022-07-26

Nature Medicine

Abstract:Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. We undertook a retrospective matched cohort study using a UK-based primary care database, Clinical Practice Research Datalink Aurum, to determine symptoms that are associated with confirmed SARS-CoV-2 infection beyond 12 weeks in non-hospitalized adults and the risk factors associated with developing persistent symptoms. We selected 486,149 adults with confirmed SARS-CoV-2 infection and 1,944,580 propensity score-matched adults with no recorded evidence of SARS-CoV-2 infection. Outcomes included 115 individual symptoms, as well as long COVID, defined as a composite outcome of 33 symptoms by the World Health Organization clinical case definition. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for the outcomes. A total of 62 symptoms were significantly associated with SARS-CoV-2 infection after 12 weeks. The largest aHRs were for anosmia (aHR 6.49, 95% CI 5.02–8.39), hair loss (3.99, 3.63–4.39), sneezing (2.77, 1.40–5.50), ejaculation difficulty (2.63, 1.61–4.28) and reduced libido (2.36, 1.61–3.47). Among the cohort of patients infected with SARS-CoV-2, risk factors for long COVID included female sex, belonging to an ethnic minority, socioeconomic deprivation, smoking, obesity and a wide range of comorbidities. The risk of developing long COVID was also found to be increased along a gradient of decreasing age. SARS-CoV-2 infection is associated with a plethora of symptoms that are associated with a range of sociodemographic and clinical risk factors.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Characteristics of long COVID and the impact of COVID-19 vaccination on long COVID 2 years following COVID-19 infection: prospective cohort study

Yoonjung Kim,Sohyun Bae,Hyun-Ha Chang,Shin-Woo Kim

DOI: https://doi.org/10.1038/s41598-023-50024-4

IF: 4.6

2024-01-10

Scientific Reports

Abstract:This prospective cohort study aimed to identify characteristics of long COVID and any potential mitigating effects of COVID-19 vaccinations in patients 24 months following COVID-19 infection. Adult patients diagnosed with COVID-19 between February 17, 2020, and March 24, 2020, were scheduled to visit the study hospital four times (6, 12, 18, and 24 months after infection) to assess their symptoms, quality of life, and mental health. Among the 235 patients, 121 (51.5%) completed the study visits. Of these, 59.5% were female, with a median age of 52 years. Mild to moderate disease severity were identified in 101 (83.4%) patients. A total of 75 participants (62.0%) were still experiencing long COVID symptoms 24 months after acute infection. Fatigue, amnesia, difficulty concentrating, and insomnia were the most common symptoms. The frequency of neuropsychiatric symptoms did not differ based on vaccination status or the number of doses received. Quality of life improved over time for the participants, but 32.2% of respondents still reported anxiety/depression at the end of the study. Overall, our cohort demonstrates that long COVID can persist up to 24 months after COVID-19 infection, affecting mental health and quality of life.

multidisciplinary sciences
A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Michael C Sneller,C Jason Liang,Adriana R Marques,Joyce Y Chung,Sujata M Shanbhag,Joseph R Fontana,Haniya Raza,Onyi Okeke,Robin L Dewar,Bryan P Higgins,Katie Tolstenko,Richard W Kwan,Kathleen R Gittens,Catherine A Seamon,Genevieve McCormack,Jacob S Shaw,Grace M Okpali,Melissa Law,Krittin Trihemasava,Brooke D Kennedy,Victoria Shi,J Shawn Justement,Clarisa M Buckner,Jana Blazkova,Susan Moir,Tae-Wook Chun,H Clifford Lane

DOI: https://doi.org/10.7326/M21-4905

Abstract:Background: A substantial proportion of persons who develop COVID-19 report persistent symptoms after acute illness. Various pathophysiologic mechanisms have been implicated in the pathogenesis of postacute sequelae of SARS-CoV-2 infection (PASC). Objective: To characterize medical sequelae and persistent symptoms after recovery from COVID-19 in a cohort of disease survivors and controls. Design: Cohort study. (ClinicalTrials.gov: NCT04411147). Setting: National Institutes of Health Clinical Center, Bethesda, Maryland. Participants: Self-referred adults with laboratory-documented SARS-CoV-2 infection who were at least 6 weeks from symptom onset were enrolled regardless of presence of PASC. A control group comprised persons with no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, recruited regardless of their current health status. Both groups were enrolled over the same period and from the same geographic area. Measurements: All participants had the same evaluations regardless of presence of symptoms, including physical examination, laboratory tests and questionnaires, cognitive function testing, and cardiopulmonary evaluation. A subset also underwent exploratory immunologic and virologic evaluations. Results: 189 persons with laboratory-documented COVID-19 (12% of whom were hospitalized during acute illness) and 120 antibody-negative control participants were enrolled. At enrollment, symptoms consistent with PASC were reported by 55% of the COVID-19 cohort and 13% of control participants. Increased risk for PASC was noted in women and those with a history of anxiety disorder. Participants with findings meeting the definition of PASC reported lower quality of life on standardized testing. Abnormal findings on physical examination and diagnostic testing were uncommon. Neutralizing antibody levels to spike protein were negative in 27% of the unvaccinated COVID-19 cohort and none of the vaccinated COVID-19 cohort. Exploratory studies found no evidence of persistent viral infection, autoimmunity, or abnormal immune activation in participants with PASC. Limitations: Most participants with COVID-19 had mild to moderate acute illness that did not require hospitalization. The prevalence of reported PASC was likely overestimated in this cohort because persons with PASC may have been more motivated to enroll. The study did not capture PASC that resolved before enrollment. Conclusion: A high burden of persistent symptoms was observed in persons after COVID-19. Extensive diagnostic evaluation revealed no specific cause of reported symptoms in most cases. Antibody levels were highly variable after COVID-19. Primary funding source: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
How does COVID-19 vaccination affect long-COVID symptoms?

Ali A. Asadi-Pooya,Meshkat Nemati,Mina Shahisavandi,Hamid Nemati,Afrooz Karimi,Anahita Jafari,Sara Nasiri,Seyyed Saeed Mohammadi,Zahra Rahimian,Hossein Bayat,Ali Akbari,Amir Emami,Owrang Eilami

DOI: https://doi.org/10.1371/journal.pone.0296680

IF: 3.7

2024-02-08

PLoS ONE

Abstract:The current study aimed to identify the association between COVID-19 vaccination and prolonged post-COVID symptoms (long-COVID) in adults who reported suffering from this condition. This was a retrospective follow-up study of adults with long-COVID syndrome. The data were collected during a phone call to the participants in January-February 2022. We inquired about their current health status and also their vaccination status if they agreed to participate. In total, 1236 people were studied; 543 individuals reported suffering from long long- COVID (43.9%). Chi square test showed that 15 out of 51 people (29.4%) with no vaccination and 528 out of 1185 participants (44.6%) who received at least one dose of any vaccine had long long- COVID symptoms (p = 0.032). In people who have already contracted COVID-19 and now suffer from long-COVID, receiving a COVID vaccination has a significant association with prolonged symptoms of long-COVID for more than one year after the initial infection. However, vaccines reduce the risk of severe COVID-19 (including reinfections) and its catastrophic consequences (e.g., death). Therefore, it is strongly recommended that all people, even those with a history of COVID-19, receive vaccines to protect themselves against this fatal viral infection.

multidisciplinary sciences
Vaccination status and long COVID symptoms among patients hospitalized with COVID-19: the WHF COVID-19 Long-term Study

K Singh,D Prabhakaran,K Nikhare,L Raspail,A Banerjee,J Narula,D Pineiro,P Perel,K Sliwa Hahnle

DOI: https://doi.org/10.1093/eurheartj/ehae666.3598

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background COVID-19 vaccinations have been found to be effective in reducing the severity of COVID-19 infection and in-hospital deaths; however, insufficient evidence exists about the effect of vaccination on long term morbidity and mortality after hospitalization in patients from low- and middle-income countries. Methods The global WHF COVID-19 Long-Term Follow-up Study recruited 2,504 COVID-19 hospitalized patients from 26 collaborating sites in 16 countries between January 2022 - June 2023. Patients were followed up , at 1, 3, 6, and 9-12 months post-discharge to examine short- and long-term physical and psycho-social outcomes. A standardised questionnaire was used to collect data on demographics, pre-existing comorbidities, COVID-19 symptoms on admission, vaccination status, and outcomes at discharge, including persisting symptoms, new onset hypertension or diabetes, major adverse cardiovascular events (MACE), and mortality. We compared persistent long COVID symptoms, MACE, and mortality outcomes up to one year by COVID-19 vaccination status. Results The majority of study participants were Asians (78%), males (56%) with a mean (SD) age of 59.2 (19.9) years and from low- and middle-income (65%), upper middle-income (20%) and high-income (15%) countries. The most commonly reported comorbidities were hypertension: 54% and diabetes: 38%. Approximately two-thirds of the patients had received at least one dose of COVID-19 vaccination prior to hospitalization. Unvaccinated patients were more likely to present with dyspnea (60% vs 53%, p-value<0.001) and acute respiratory infection (15% vs 9%, p-value<0.001) during hospitalization. Unvaccinated patients also had twice the in-hospital mortality rate, compared with vaccinated patients (6% vs 3%, p-value<0.001). Unvaccinated patients had a greater incidence of MACE (23% vs 18%, p-value=0.016) during hospitalization and across all follow-up visits. Unvaccinated patients also had a higher mortality rate across all follow-up visits (mortality at one year post-discharge 14% vs 10%, p<0.001). At the 9-12 month follow-up, about a quarter of the patients had at least one long COVID symptom, but unvaccinated patients had a higher rate of long COVID symptoms, including fatigue (23% vs 14%, p<0.001), palpitations (17% to 7%, p-value<0.001), and anxiety (13% to 7%, p=0.002). Conclusions Our data highlight the long-term protective effect of COVID-19 vaccination on reducing morbidity and mortality among COVID-19 patients after hospital discharge. However, a substantial proportion of COVID-19 vaccinated patients still showed persistent long COVID symptoms (22%) and mortality (10%). Future research is needed to investigate individual- and health system-level factors contributing to poor health outcomes post-COVID-19 infection.

cardiac & cardiovascular systems
Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

Yoonjung Kim,Sohyun Bae,Hyun-Ha Chang,Shin-Woo Kim

DOI: https://doi.org/10.1038/s41598-023-36995-4

IF: 4.6

2023-07-11

Scientific Reports

Abstract:Abstract There has been an increasing interest in the long-term impact of long COVID. However, only a few studies have investigated the clinical manifestations of long COVID 24 months after acute COVID infection. In this study, prospective online surveys were conducted in adults previously diagnosed with coronavirus disease 2019 (COVID-19) in South Korea between February 13 and March 13, 2020, at 6, 12, and 24 months after COVID-19. We investigated self-reported symptoms and the EuroQol-5-dimension index. Among 900 individuals enrolled initially, 150 completed all 3 surveys. After excluding the cases of COVID-19 reinfection, 132 individuals were included in the final analysis. Among the 132 participants, 94 (71.2%) experienced symptoms of long COVID. The most frequently reported symptoms were fatigue (34.8%), amnesia (30.3%), concentration difficulties (24.2%), insomnia (20.5%), and depression (19.7%). Notably, no significant differences were noted in the incidence of long COVID at 24 months in terms of the number of vaccinations received. Although the neuropsychiatric quality of life improved over time, it continued to affect 32.7% of participants. Symptoms of long COVID, particularly neuropsychiatric symptoms, tend to persist over time, and COVID-19 vaccination or the number of vaccinations received may not significantly affect the incidence of long COVID.

multidisciplinary sciences
Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations

Liane S Canas,Erika Molteni,Jie Deng,Carole H Sudre,Benjamin Murray,Eric Kerfoot,Michela Antonelli,Khaled Rjoob,Joan Capdevila Pujol,Lorenzo Polidori,Anna May,Marc F Österdahl,Ronan Whiston,Nathan J Cheetham,Vicky Bowyer,Tim D Spector,Alexander Hammers,Emma L Duncan,Sebastien Ourselin,Claire J Steves,Marc Modat

DOI: https://doi.org/10.1016/S2589-7500(23)00056-0

Abstract:Background: Self-reported symptom studies rapidly increased understanding of SARS-CoV-2 during the COVID-19 pandemic and enabled monitoring of long-term effects of COVID-19 outside hospital settings. Post-COVID-19 condition presents as heterogeneous profiles, which need characterisation to enable personalised patient care. We aimed to describe post-COVID-19 condition profiles by viral variant and vaccination status. Methods: In this prospective longitudinal cohort study, we analysed data from UK-based adults (aged 18-100 years) who regularly provided health reports via the Covid Symptom Study smartphone app between March 24, 2020, and Dec 8, 2021. We included participants who reported feeling physically normal for at least 30 days before testing positive for SARS-CoV-2 who subsequently developed long COVID (ie, symptoms lasting longer than 28 days from the date of the initial positive test). We separately defined post-COVID-19 condition as symptoms that persisted for at least 84 days after the initial positive test. We did unsupervised clustering analysis of time-series data to identify distinct symptom profiles for vaccinated and unvaccinated people with post-COVID-19 condition after infection with the wild-type, alpha (B.1.1.7), or delta (B.1.617.2 and AY.x) variants of SARS-CoV-2. Clusters were then characterised on the basis of symptom prevalence, duration, demography, and previous comorbidities. We also used an additional testing sample with additional data from the Covid Symptom Study Biobank (collected between October, 2020, and April, 2021) to investigate the effects of the identified symptom clusters of post-COVID-19 condition on the lives of affected people. Findings: We included 9804 people from the COVID Symptom Study with long COVID, 1513 (15%) of whom developed post-COVID-19 condition. Sample sizes were sufficient only for analyses of the unvaccinated wild-type, unvaccinated alpha variant, and vaccinated delta variant groups. We identified distinct profiles of symptoms for post-COVID-19 condition within and across variants: four endotypes were identified for infections due to the wild-type variant (in unvaccinated people), seven for the alpha variant (in unvaccinated people), and five for the delta variant (in vaccinated people). Across all variants, we identified a cardiorespiratory cluster of symptoms, a central neurological cluster, and a multi-organ systemic inflammatory cluster. These three main clusers were confirmed in a testing sample. Gastrointestinal symptoms clustered in no more than two specific phenotypes per viral variant. Interpretation: Our unsupervised analysis identified different profiles of post-COVID-19 condition, characterised by differing symptom combinations, durations, and functional outcomes. Our classification could be useful for understanding the distinct mechanisms of post-COVID-19 condition, as well as for identification of subgroups of individuals who might be at risk of prolonged debilitation. Funding: UK Government Department of Health and Social Care, Chronic Disease Research Foundation, The Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, UK Alzheimer's Society, and ZOE.
Association of vaccine status, reinfections, and risk factors with Long COVID syndrome

Maria Elena Romero-Ibarguengoitia,Juan Francisco Rodríguez-Torres,Arnulfo Garza-Silva,Andrea Rivera-Cavazos,Devany Paola Morales-Rodriguez,Mauricio Hurtado-Cabrera,Ricardo Kalife-Assad,Diana Villarreal-Parra,Alejandro Loose-Esparza,Juan José Gutiérrez-Arias,Yaressi Guadalupe Mata-Porras,Daniela Abigail Ojeda-Salazar,Miguel Angel Sanz-Sánchez,Arnulfo González-Cantú,Elena Azzolini,Maria Rescigno

DOI: https://doi.org/10.1038/s41598-024-52925-4

IF: 4.6

2024-02-03

Scientific Reports

Abstract:The COVID-19 pandemic had a profound global impact, characterized by a high fatality rate and the emergence of enduring consequences known as Long COVID. Our study sought to determine the prevalence of Long COVID syndrome within a population of Northeastern Mexico, correlating it with patients' comorbidities, number of COVID-19 reinfection, and vaccination status. Employing an observational cross-sectional approach, we administered a comprehensive questionnaire covering medical history, demographics, vaccination status, COVID-related symptoms, and treatment. Our participant cohort included 807 patients, with an average age of 41.5 (SD 13.6) years, and women accounting 59.3% of the cohort. The follow-up was 488 (IQR 456) days. One hundred sixty-eight subjects (20.9%) met Long COVID criteria. Long COVID-19 was more prevalent when subjects had reinfections (p = 0.02) and less frequent when they had a complete vaccination scheme (p = 0.05). Through logistic regression, we found that male gender (OR 0.5, p ≤ 0.001), blood types of AB− (OR 0.48, p = 0.003) and O− (OR 0.27, p ≤ 0.001) in comparison with A+ and two doses of vaccines (OR 0.5, p = 006) to be protective factors against Long COVID; while higher BMI (OR 1.04, p = 0.005) was a risk factor. We saw that the prevalence of Long COVID was different within vaccinated patients and specific blood types, while being female and a higher BMI were associated with an increased risk of having long-COVID.

multidisciplinary sciences
Distinguishing features of Long COVID identified through immune profiling

Jon Klein,Jamie Wood,Jillian Jaycox,Rahul M. Dhodapkar,Peiwen Lu,Jeff R. Gehlhausen,Alexandra Tabachnikova,Kerrie Greene,Laura Tabacof,Amyn A. Malik,Valter Silva Monteiro,Julio Silva,Kathy Kamath,Minlu Zhang,Abhilash Dhal,Isabel M. Ott,Gabrielee Valle,Mario Peña-Hernandez,Tianyang Mao,Bornali Bhattacharjee,Takehiro Takahashi,Carolina Lucas,Eric Song,Dayna Mccarthy,Erica Breyman,Jenna Tosto-Mancuso,Yile Dai,Emily Perotti,Koray Akduman,Tiffany J. Tzeng,Lan Xu,Anna C. Geraghty,Michelle Monje,Inci Yildirim,John Shon,Ruslan Medzhitov,Denyse Lutchmansingh,Jennifer D. Possick,Naftali Kaminski,Saad B. Omer,Harlan M. Krumholz,Leying Guan,Charles S. Dela Cruz,David van Dijk,Aaron M. Ring,David Putrino,Akiko Iwasaki

DOI: https://doi.org/10.1038/s41586-023-06651-y

IF: 64.8

2023-09-26

Nature

Abstract:Post-acute infection syndromes (PAIS) may develop after acute viral disease 1 . Infection with SARS-CoV-2 can result in the development of a PAIS known as "Long COVID" (LC). Individuals with LC frequently report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfunctions 2–4 ; however, the biological processes associated with the development and persistence of these symptoms are unclear. Here, 273 individuals with or without LC were enrolled in a cross-sectional study that included multi-dimensional immune phenotyping and unbiased machine learning methods to identify biological features associated with LC. Marked differences were noted in circulating myeloid and lymphocyte populations relative to matched controls, as well as evidence of exaggerated humoral responses directed against SARS-CoV-2 among participants with LC. Further, higher antibody responses directed against non-SARS-CoV-2 viral pathogens were observed among individuals with LC, particularly Epstein-Barr virus. Levels of soluble immune mediators and hormones varied among groups, with cortisol levels being lower among participants with LC. Integration of immune phenotyping data into unbiased machine learning models identified key features most strongly associated with LC status. Collectively, these findings may help guide future studies into the pathobiology of LC and aid in developing relevant biomarkers.

multidisciplinary sciences
Vaccine Effectiveness Against Long COVID in Children

Hanieh Razzaghi,Christopher B Forrest,Kathryn Hirabayashi,Qiong Wu,Andrea Allen,Suchitra Rao,Yong Chen,H Timothy Bunnell,Elizabeth A Chrischilles,Lindsay G Cowell,Mollie R Cummins,David A Hanauer,Miranda Higginbotham,Benjamin D Horne,Carol R Horowitz,Ravi Jhaveri,Susan Kim,Aaron Mishkin,Jennifer A Muszynski,Susanna Naggie,Nathan M Pajor,Anuradha Paranjape,Hayden T Schwenk,Marion R Sills,Yacob G Tedla,David A Williams,Charles Bailey,Christopher B. Forrest,H. Timothy Bunnell,Elizabeth A. Chrischilles,Lindsay G. Cowell,Mollie R. Cummins,David A. Hanauer,Benjamin D. Horne,Carol R. Horowitz,Jennifer A. Muszynski,Nathan M. Pajor,Hayden T. Schwenk,Marion R. Sills,Yacob G. Tedla,David A. Williams

DOI: https://doi.org/10.1542/peds.2023-064446

2024-01-16

PEDIATRICS

Abstract:OBJECTIVE Vaccination reduces the risk of acute COVID-19 in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5-17 years. METHODS This retrospective cohort study used data from 17 health systems in the RECOVER PCORnet electronic health record (EHR) Program for visits after vaccine availability. Conditional logistic regression was used to estimate VE against long COVID with matching on age group (5-11, 12-17) and time period and adjustment for sex, ethnicity, health system, comorbidity burden, and pre-exposure health care utilization. We examined both probable (symptom-based) and diagnosed long COVID in the year following vaccination. RESULTS The vaccination rate was 56% in the cohort of 1,037,936 children. The incidence of probable long COVID was 4.5% among patients with COVID-19, while diagnosed long COVID was 0.7%. Adjusted vaccine effectiveness within 12 months was 35.4% (95 CI 24.5 – 44.5) against probable long COVID and 41.7% (15.0 – 60.0) against diagnosed long COVID. VE was higher for adolescents 50.3% [36.3 – 61.0]) than children aged 5-11 (23.8% [4.9 – 39.0]). VE was higher at 6 months (61.4% [51.0 – 69.6]) but decreased to 10.6% (-26.8 – 37.0%) at 18-months. DISCUSSION This large retrospective study shows a moderate protective effect of SARS-CoV-2 vaccination against long COVID. The effect is stronger in adolescents, who have higher risk of long COVID, and wanes over time. Understanding VE mechanism against long COVID requires more study, including EHR sources and prospective data.

pediatrics
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Chansavath Phetsouphanh,Brendan Jacka,Sara Ballouz,Katherine J. L. Jackson,Daniel B. Wilson,Bikash Manandhar,Vera Klemm,Hyon-Xhi Tan,Adam Wheatley,Anupriya Aggarwal,Anouschka Akerman,Vanessa Milogiannakis,Mitchell Starr,Phillip Cunningham,Stuart G. Turville,Stephen J. Kent,Anthony Byrne,Bruce J. Brew,David R. Darley,Gregory J. Dore,Anthony D. Kelleher,Gail V. Matthews

DOI: https://doi.org/10.1038/s41467-024-47720-8

IF: 16.6

2024-04-17

Nature Communications

Abstract:Abstract This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, and higher neutralizing capacity up to 8 months post-infection. Increased spike-specific and nucleocapsid-specific CD4 + T cells, PD-1, and TIM-3 expression on CD4 + and CD8 + T cells were observed at 3 and 8 months, but these differences do not persist at 24 months. Some LC participants had detectable IFN-γ and IFN-β, that was attributed to reinfection and antigen re-exposure. Single-cell RNA sequencing at the 24 month timepoint shows similar immune cell proportions and reconstitution of naïve T and B cell subsets in LC and MC. No significant differences in exhaustion scores or antigen-specific T cell clones are observed. These findings suggest resolution of immune activation in LC and return to comparable immune responses between LC and MC over time. Improvement in self-reported health-related quality of life at 24 months was also evident in the majority of LC (62%). PTX3, CRP levels and platelet count are associated with improvements in health-related quality of life.

multidisciplinary sciences
Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms

Yeming Wang,Li Guo,Dan Cui,Hui Zhang,Qiao Zhang,Lili Ren,Geng Wang,Xueyang Zhang,Tingxuan Huang,Lan Chen,Lixue Huang,Xinming Wang,Jinchuan Zhong,Ying Wang,Hui Li,Jianwei Wang,Bin Cao

DOI: https://doi.org/10.1093/ofid/ofae137

2024-03-28

Open Forum Infectious Diseases

Abstract:Abstract The immune mechanisms of long coronavirus disease 2019 (COVID) are not yet fully understood. We aimed to investigate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific memory immune responses in discharged COVID-19 patients with and without long COVID symptoms. In this cross-sectional study, we included 1041 hospitalized COVID-19 patients with the original virus strain in Wuhan (China) 12 months after initial infection. We simultaneously conducted a questionnaire survey and collected peripheral blood samples from the participants. Based on the presence or absence of long COVID symptoms during the follow-up period, we divided the patients into 2 groups: a long COVID group comprising 480 individuals and a convalescent group comprising 561 individuals. Both groups underwent virus-specific immunological analyses, including enzyme-linked immunosorbent assay, interferon-γ-enzyme-linked immune absorbent spot, and intracellular cytokine staining. At 12 months after infection, 98.5% (1026/1041) of the patients were found to be seropositive and 93.3% (70/75) had detectable SARS-CoV-2-specific memory T cells. The long COVID group had significantly higher levels of receptor binding domain (RBD)–immunoglobulin G (IgG) levels, presented as OD450 values, than the convalescent controls (0.40 ± 0.22 vs 0.37 ± 0.20; P = .022). The magnitude of SARS-CoV-2-specific T-cell responses did not differ significantly between groups, nor did the secretion function of the memory T cells. We did not observe a significant correlation between SARS-CoV-2-IgG and magnitude of memory T cells. This study revealed that long COVID patients had significantly higher levels of RBD-IgG antibodies when compared with convalescent controls. Nevertheless, we did not observe coordinated SARS-CoV-2-specific cellular immunity. As there may be multiple potential causes of long COVID, it is imperative to avoid adopting a “one-size-fits-all” approach to future treatment modalities.

immunology,infectious diseases,microbiology
Restrained memory CD8 T cell responses favors viral persistence and elevated IgG responses in patients with severe Long COVID

Lucie Rodriguez,Ziyang Tan,Tadepally Lakshmikanth,Jun Wang,Hugo Barcenilla,Zoe Swank,Fanglei Zuo,Hassan Abolhassani,Ana Jimena Pavlovitch-Bedzyk,Chunlin Wang,Laura Gonzalez,Constantin Habimana Mugabo,Anette Johnsson,Yang Chen,Anna James,Jaromir Mikes,Linn Kleberg,Christopher Sundling,Mikael Björnson,Malin Nygren Bonnier,Marcus Ståhlberg,Michael Runold,Sophia Björkander,Erik Melén,Isabelle Meyts,Johan Van Weyenbergh,Qian-Pan Hammarström,Mark M Davis,David R. Walt,Nils Landegren,COVID Human Genetic Effort,Alessandro Aiuti,Giorgio Casari,Jean-Laurent Casanova,Marc Jamoulle,Judith Bruchfeld,Petter Brodin

DOI: https://doi.org/10.1101/2024.02.11.24302636

2024-02-13

Abstract:During the COVID-19 pandemic it was widely described that certain individuals infected by SARS-CoV-2 experience persistent disease signs and symptoms, Long COVID, which in some cases is very severe with life changing consequences. To maximize our chances of identifying the underpinnings of this illness, we have focused on 121 of the most severe cases from >1000 patients screened in specialized clinics in Sweden and Belgium. We restricted this study to subjects with objective measures of organ damage or dysfunction, >3 months following a verified, but mild-to-moderate SARS-CoV-2 infection. By performing systems-level immunological testing and comparisons to controls fully convalescent following a similar mild/moderate COVID-19 episode, we identify elevated serological responses to SARS-CoV-2 in severe Long COVID suggestive of chronic antigen stimulation. Persistent viral reservoirs have been proposed in Long COVID and using multiple orthogonal methods for detection of SARS-CoV-2 RNA and protein in plasma we identify a subset of patients with detectable antigens, but with minimal overlap across assays, and no correlation to symptoms or immune measurements. Elevated serologic responses to SARS-CoV-2 on the other hand were inversely correlated with clonally expanded memory CD8 T cells, indicating that restrained clonal expansion enables viral persistence, chronic antigen exposure and elevated IgG responses, even if antigen-detection in blood is not universally possible.

Infectious Diseases (except HIV/AIDS)
The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID

Maddalena Noviello,Rebecca De Lorenzo,Raniero Chimienti,Norma Maugeri,Claudia De Lalla,Gabriel Siracusano,Nicola Ivan Lorè,Paola Maria Vittoria Rancoita,Federica Cugnata,Elena Tassi,Stefania Dispinseri,Danilo Abbati,Valeria Beretta,Eliana Ruggiero,Francesco Manfredi,Aurora Merolla,Elisa Cantarelli,Cristina Tresoldi,Claudia Pastori,Roberta Caccia,Francesca Sironi,Ilaria Marzinotto,Fabio Saliu,Silvia Ghezzi,Vito Lampasona,Elisa Vicenzi,Paola Cinque,Angelo Andrea Manfredi,Gabriella Scarlatti,Paolo Dellabona,Lucia Lopalco,Clelia Di Serio,Mauro Malnati,Fabio Ciceri,Patrizia Rovere-Querini,Chiara Bonini

DOI: https://doi.org/10.3389/fimmu.2024.1381091

IF: 7.3

2024-07-30

Frontiers in Immunology

Abstract:Introduction: SARS-CoV-2 pandemic still poses a significant burden on global health and economy, especially for symptoms persisting beyond the acute disease. COVID-19 manifests with various degrees of severity and the identification of early biomarkers capable of stratifying patient based on risk of progression could allow tailored treatments. Methods: We longitudinally analyzed 67 patients, classified according to a WHO ordinal scale as having Mild, Moderate, or Severe COVID-19. Peripheral blood samples were prospectively collected at hospital admission and during a 6-month follow-up after discharge. Several subsets and markers of the innate and adaptive immunity were monitored as putative factors associated with COVID-19 symptoms. Results: More than 50 immunological parameters were associated with disease severity. A decision tree including the main clinical, laboratory, and biological variables at admission identified low NK-cell precursors and CD14 + CD91 + monocytes, and high CD8 + Effector Memory T cell frequencies as the most robust immunological correlates of COVID-19 severity and reduced survival. Moreover, low regulatory B-cell frequency at one month was associated with the susceptibility to develop long COVID at six months, likely due to their immunomodulatory ability. Discussion: These results highlight the profound perturbation of the immune response during COVID-19. The evaluation of specific innate and adaptive immune-cell subsets allows to distinguish between different acute and persistent COVID-19 symptoms.

immunology

Genetics of the polycross

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Attributes and predictors of long COVID

Effect of covid-19 vaccination on long covid: systematic review

Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults

SARS-CoV-2-specific CD8+ T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years

Symptoms and risk factors for long COVID in non-hospitalized adults

Characteristics of long COVID and the impact of COVID-19 vaccination on long COVID 2 years following COVID-19 infection: prospective cohort study

A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

How does COVID-19 vaccination affect long-COVID symptoms?

Vaccination status and long COVID symptoms among patients hospitalized with COVID-19: the WHF COVID-19 Long-term Study

Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations

Association of vaccine status, reinfections, and risk factors with Long COVID syndrome

Distinguishing features of Long COVID identified through immune profiling

Vaccine Effectiveness Against Long COVID in Children

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms

Restrained memory CD8 T cell responses favors viral persistence and elevated IgG responses in patients with severe Long COVID

The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID